Who Paid My Doc
Roy Fleischmann
Dallas, TX Medical Doctor
NPI 1467451146 CMS profile 65751
8144 Walnut Hill Ln, Suite 800, Dallas, TX 75231
General payments
$1,046,887
Research payments
$86,873
Ownership & investment interest
$0
Research they led as principal investigator
$2,729,498
Through program year 2025, Roy Fleischmann of Dallas, TX is reported in the CMS Open Payments database as having received $1,046,887 across 982 general payments and $86,873 in research payments paid to them. Separately, studies naming them as principal investigator received $2,729,498 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
14 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $81,560 | 154 | |
| 2025 | Research | $780 | 1 | |
| 2024 | General | $80,953 | 105 | |
| 2024 | Research | $10,820 | 3 | |
| 2023 | General | $114,701 | 137 | |
| 2023 | Research | $7,132 | 10 | |
| 2022 | General | $150,610 | 153 | |
| 2022 | Research | $17,490 | 11 | |
| 2021 | General | $170,861 | 51 | |
| 2021 | Research | $26,310 | 14 | |
| 2020 | General | $148,819 | 63 | |
| 2020 | Research | $13,701 | 16 | |
| 2019 | General | $299,383 | 319 | |
| 2019 | Research | $10,641 | 18 |
Beside peers
- Roy Fleischmann
- Texas median
- Middle half of Texas
- National median
In program year 2025, general payments to Roy Fleischmann were reported at $81,560. Among 86,592 Texas profiles paid that year, the median was $188 and the middle half received between $55 and $669.
Show as a table
| Year | Roy Fleischmann | Texas median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $299,383 | $191 | $56–$744 | $163 |
| 2020 | $148,819 | $125 | $38–$452 | $114 |
| 2021 | $170,861 | $150 | $43–$543 | $132 |
| 2022 | $150,610 | $169 | $50–$606 | $149 |
| 2023 | $114,701 | $183 | $53–$639 | $160 |
| 2024 | $80,953 | $188 | $55–$666 | $164 |
| 2025 | $81,560 | $188 | $55–$669 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
1,055 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.